.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The Indian pharmaceutical market recently witnessed a significant shift following the strict enforcement of WHO ORS Labelling Norms. According to recent data, sales for oral rehydration solutions (ORS) dropped by 26% in March. This decline directly follows the government's crackdown on sugary and fruit-based beverages that previously used the ORS label. Consequently, pharmaceutical companies are adjusting to a market where only medically compliant formulations can use the therapeutic designation. Experts suggest that the removal of misleading products is the primary driver behind this unusual seasonal sales pattern.
The Food Safety and Standards Authority of India (FSSAI) recently implemented a landmark ban to protect vulnerable patients. Specifically, manufacturers can no longer label sugary drinks as ORS unless they meet WHO ORS Labelling Norms. Previously, many beverages masqueraded as medical rehydration salts despite containing excessive sugar levels. These sugary substitutes often contained ten times the glucose amount recommended for therapeutic use. Therefore, clinicians noticed that these products frequently worsened diarrhea in pediatric patients rather than treating it effectively. Moreover, the new regulations mandate that therapeutic ORS must fall under the purview of the CDSCO instead of the FSSAI.
PharmaTrac reports indicate that the sector's value growth declined significantly this year due to these regulatory changes. For example, February and March sales stood at ₹80 crore and ₹85 crore, down from over ₹110 crore in previous years. Even market leaders like Electral saw a 7% decline in moving annual total sales. Additionally, the FSSAI's intervention dismantled long-standing marketing architectures built around these non-compliant brands. However, medical experts argue this correction is essential for long-term public health. Dr. Sivaranjani Santosh highlighted that misbranded products previously led to numerous child hospitalizations across India. Consequently, the medical community is now steering parents away from commercial formulations altogether.
Q1: Why are ORS sales in India declining despite the summer season?
Sales are declining because new FSSAI regulations prevent sugary and fruit-based drinks from using the 'ORS' label. This has led to the withdrawal of many misbranded products that previously inflated market figures.
Q2: Who regulates therapeutic ORS products under the new Indian norms?
Manufacturers of genuine therapeutic ORS must now seek permission from the Central Drugs Standard Control Organisation (CDSCO). This ensures that products labeled as ORS meet strict medical standards rather than just general food safety rules.
Q3: Why were sugary drinks marketed as ORS considered a health concern?
Many commercial drinks contained 110-120g of sugar per liter, which is nearly ten times the amount permitted by WHO standards. This high sugar content can cause osmotic diarrhea, worsening dehydration in children instead of treating it.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
FSSAI enforces WHO ORS labelling norms, banning sugary drinks from the ORS category. This shift led to a 26% decline in March market value across India....
4 months ago
A large NHANES cohort study reveals that higher Healthy Eating Index scores significantly reduce all-cause mortality risk in CKD patients by 45%. This analysis highlights the importance of comprehensive diet quality and medical nutrition therapy in renal care to optimize long-term clinical survival.
Today
A prospective cohort study demonstrates that poor adolescent sleep quality, especially long sleep latency and reduced efficiency, increases dysmenorrhea severity in young adulthood. Addressing adolescent rest patterns offers a critical preventive avenue for clinicians.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Today
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
